ADCIRCA (tadalafil), an oral treatment for pulmonary arterial hypertension, is a selective inhibitor of cyclic guanosine monophosphate (cGMP)specific phosphodiesterase type 5 (PDE5).
Pulmonary Arterial Hypertension
ADCIRCA® is indicated for the treatment of pulmonary arterial hypertension (PAH) (WHO Group 1) to improve exercise ability. Studies establishing effectiveness included predominately patients with NYHA Functional Class II III symptoms and etiologies of idiopathic or heritable PAH (61%) or PAH associated with connective tissue diseases (23%).
Media Articles Related to Adcirca (Tadalafil)
Combo Tx Aids in Scleroderma PAH (CME/CE)
Source: MedPage Today Pulmonology [2017.01.06]
(MedPage Today) -- Trial data support ambrisentan plus tadalafil
Published Studies Related to Adcirca (Tadalafil)
Urodynamic effects of the combination of tamsulosin and daily tadalafil in men
with lower urinary tract symptoms secondary to benign prostatic hyperplasia: a
randomized, placebo-controlled clinical trial. 
study (UDS)... CONCLUSIONS: The association of tamsulosin/tadalafil reduces detrusor pressure at
The role of initial success rates and other factors in determining reliability of
outcomes of phosphodiesterase inhibitor therapy for erectile dysfunction: a
pooled analysis of 17 placebo-controlled trials of tadalafil for use as needed. 
Profile questions 2 and 3... CONCLUSIONS: The findings affirm the reliability of successful outcomes with
Tadalafil once daily and extracorporeal shock wave therapy in the management of patients with Peyronie's disease and erectile dysfunction: results from a prospective randomized trial. [2011.11.15]
Extracorporeal shock wave therapy improves erectile function in patients with Peyronie's disease. However, erectile dysfunction still persists in many cases... In conclusion extracorporeal shock wave therapy plus tadalafil 5 mg once daily may represent a valid conservative strategy for the management of patients with Peyronie's disease and erectile dysfunction.
Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial. [2011.11]
BACKGROUND: Tadalafil is being investigated for the treatment of lower urinary tract symptoms (LUTS) suggestive of benign prostatic hyperplasia (BPH-LUTS). OBJECTIVE: To assess efficacy, including onset, and safety of tadalafil on BPH-LUTS and the subject's and clinician's perception of changes in urinary symptoms... CONCLUSIONS: Tadalafil 5mg once daily for 12 wk resulted in a clinically meaningful reduction in total IPSS results as early as 1 wk and achieved statistical significance at 4 wk in men with BPH-LUTS. The adverse event profile was consistent with that previously reported in men with ED. TRIAL REGISTRATION: This clinical trial is registered on the clinicaltrials.gov website (http://www.clinicaltrials.gov). The registration number is NCT00827242. Copyright (c) 2011. Published by Elsevier B.V.
Clinical efficacy of phosphodiesterase-5 inhibitor tadalafil in Eisenmenger syndrome--a randomized, placebo-controlled, double-blind crossover study. [2011.09]
OBJECTIVES: In a randomized double-blind crossover trial, we compared the efficacy of phosphodiesterase-5 (PDE-5) inhibitor tadalafil with placebo in patients of Eisenmenger Syndrome (ES). The primary end point was the change in 6-minute walk test distance (6 MWD). Secondary end points were the effect of the drug on systemic oxygen saturation (SO(2) ), pulmonary vascular resistance (PVR), systemic vascular resistance (SVR), effective pulmonary blood flow (EPBF), and World Health Organization (WHO) functional class. BACKGROUND: ES is a disorder with limited treatment options. Uncontrolled studies have shown PDE-5 inhibitors to be beneficial in patients of ES... CONCLUSION: In this first short-term placebo-controlled trial of tadalafil in patients of ES, the drug was well tolerated and significantly improved exercise capacity, functional class, SO(2) , and pulmonary hemodynamics. (c) 2011 Copyright the Authors. Congenital Heart Disease (c) 2011 Wiley Periodicals, Inc.
Clinical Trials Related to Adcirca (Tadalafil)
A Clinical Trial of Ambrisentan and Tadalafil in Pulmonary Arterial Hypertension Associated With Systemic Sclerosis [Active, not recruiting]
This will be a 36-week, randomized, double-blind, parallel group study comparing the effects
of tadalafil monotherapy, ambrisentan monotherapy and combination therapy with tadalafil
and ambrisentan in patients with PAH-SSc. Standard outcome measures such as six-minute walk
distance (6MWD), NYHA classification, and hemodynamic measurements will be assessed, as well
as novel functional measures of RV-PV function including the transthoracic echocardiogram
parameter tricuspid annular plane systolic ejection (TAPSE), contrast-enhanced cardiac MRI
and heart rate variability assessed by Holter monitoring. This design (excluding a
placebo-placebo arm) was selected for ethical concerns and to provide optimal efficiency and
active therapy to all study subjects. It also allows for comparisons between the two
monotherapies and with combination therapy.
Study of Tadalafil for the Treatment of Diabetic Patients With Symptoms of Upset Stomach and Delayed Stomach Emptying [Completed]
The purposes of this study are to determine whether an experimental drug known as tadalafil
can reduce symptoms of dyspepsia (fullness after eating, inability to finish a regular meal,
bloating, discomfort or pain in the upper abdomen, belching after meals, nausea, vomiting)
in diabetic patients, and/or reduce the amount of time the stomach takes to empty the
contents of a standard meal. The safety of tadalafil given once daily for 8 weeks in this
population will also be studied.
Study of Tadalafil Once-a Day for 12 Weeks in Men With Signs and Symptoms of Benign Prostatic Hyperplasia [Completed]
This is a randomized, double-blind, placebo-controlled, parallel-design, multinational,
12-week study to compare the efficacy, dose response, and safety of tadalafil once a day
versus placebo in men with signs and symptoms of benign prostatic hyperplasia, including
lower urinary tract symptoms.
PHIRST-1: Tadalafil in the Treatment of Pulmonary Arterial Hypertension [Completed]
Study the Safety and Effectiveness of Tadalafil on High Blood Pressure in the Blood Vessel Going From the Heart to the Lungs [Completed]
Study to determine the long term safety of tadalafil in patients with increased blood
pressure in the blood vessel that carries blood from the right heart to the lungs and to see
if it will keep the disease from getting worse.
Reports of Suspected Adcirca (Tadalafil) Side Effects
Vision Blurred (14),
Fluid Retention (13),
OFF Label USE (11),
Fatigue (11), more >>
PATIENT REVIEWS / RATINGS / COMMENTS
Based on a total of 1 ratings/reviews, Adcirca has an overall score of 2. The effectiveness score is 2 and the side effect score is 6. The scores are on ten point scale: 10 - best, 1 - worst.
Adcirca review by 49 year old male patient
|Overall rating:|| || |
|Effectiveness:|| || Ineffective|
|Side effects:|| || Moderate Side Effects|
|Condition / reason:|| || Difficulty getting/holding erection|
|Dosage & duration:|| || 20mg taken once for the period of 36 hours|
|Other conditions:|| || none|
|Other drugs taken:|| || none|
|Benefits:|| || I might as well have not taken it at all. I noticed no difference in trying to achieve an erection than without it. When erection was achieved it went away quickly. The strength of erection was minimal. Not impressed at all.|
|Side effects:|| || Massive headache an hour or so after ingesting the pill as well as heavy clogged sinuses. Found it hard to breath. Felt like flu symptoms.|
|Comments:|| || The only thing this pill gave me was strong flu-like symptoms. I'll try it again and see if the results are better but so far I'm not impressed at all and $80 in the hole. Complete waste of money and suffered flu symptoms the entire next day. It's very difficult to be in the mood for sex when you feel sick with a throbbing headache.|
Page last updated: 2017-01-06